-
Mashup Score: 9Methodological challenges in the development of endpoints for myelofibrosis clinical trials - 4 hour(s) ago
Myelofibrosis is a myeloid neoplasm characterised by the presence of JAK2, CALR, or MPL mutations (with a 90% mutation frequency) and trilineage myeloid proliferation with prominent megakaryocyte atypia. People with myelofibrosis have a lower survival rate and poorer quality of life than healthy individuals. Therapy for myelofibrosis uses Janus kinase inhibitors, which reduce splenomegaly and alleviate symptoms. Regulatory approvals for Janus kinase inhibitors have focused on this dual endpoint.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 140Chronic myeloid leukaemia - 9 day(s) ago
In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of a fatal disease to a disorder amenable simply to lifelong oral medication and compatible with a normal lifespan. This change has been made possible by a deep understanding of the molecular pathogenesis and a determination to develop targeted and selective drugs. This Seminar summarises the presentation, pathophysiology, diagnosis and monitoring technology, treatment options, side-effects, and outcomes of chronic myeloid leukaemia, and discusses the possibility of cure—ie, stable undetectable or low level disease in the absence of medication.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 140Chronic myeloid leukaemia - 9 day(s) ago
In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of a fatal disease to a disorder amenable simply to lifelong oral medication and compatible with a normal lifespan. This change has been made possible by a deep understanding of the molecular pathogenesis and a determination to develop targeted and selective drugs. This Seminar summarises the presentation, pathophysiology, diagnosis and monitoring technology, treatment options, side-effects, and outcomes of chronic myeloid leukaemia, and discusses the possibility of cure—ie, stable undetectable or low level disease in the absence of medication.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Nico Gagelmann: Honored to receive one of the best young abstracts awards of EBMT24 - OncoDaily - 15 day(s) ago
Nico Gagelmann: Honored to receive one of the best young abstracts awards of EBMT24 / cancer, EBMT Trainee Committee, EBMT24, Nico Gagelmann, OncoDaily,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
BL accounts for around 2% of all adult NHL with a higher incidence in patients with immunodeficiency and in patients who have HIV infection. There is an endemic pediatric subtype in equatorial Africa, which is strongly associated with EBV. The clinical course of BL…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors - 2 month(s) ago
Leukemia – Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 88Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee - 2 month(s) ago
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoieti
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 87Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee - 2 month(s) ago
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoieti
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis - 2 month(s) ago
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor–naive …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy? - 2 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
We need to focus on relevant endpoints in myelofibrosis: eg overall survival and progression-free survival. Methodological challenges in the development of endpoints for myelofibrosis clinical trials @TheLancetHaem #mpnsm https://t.co/7FxmLKB9yL